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DrMichael Madani (La Jolla, Calif). It is a pleasure to see that
CTEPH and PEA are finally getting recognition that they are no
longer obscure diseases and obscure operations that are performed
in a few centers around the world, but still there is a lot of work that
needs to be done and is ahead of us.
As you know, we have performed more than 3000 of these op-
erations at our institutions, and our referrals are increasing and
there are many patients with distal disease, but we believe the dis-
ease is still severely underdiagnosed in the United States and
around the world.
Furthermore, as you pointed out, what is evenmore disturbing is
that patients are not being referred for surgery because of lack of
experience in determining who is and is not operable in so-called
distal disease. Congratulations on showing that even in this patient
population, you can achieve significant hemodynamic improve-
ment and potential cure.
I have 3 questions for you. First, I’m puzzled by your technique
of multiple intermittent circulatory arrest of 5 to 10 minutes, each
of which results in approximately 100 minutes of circulatory arrest
and 6 hours of bypass. Why do you use this technique?
Dr Grazioli. The technique we use consists of moderate hypo-
thermia at 24 degrees, short arrest session from 7 to 10minutes, and
reperfusion periods for more than 5 minutes. We arrived at this last
management with a gradual change. We use this technique for 2
principal reasons: to have more neurologic protection because of
reperfusion periods and monitoring of cerebral blood flow satura-
tion and to allow a longer time for dissection to accurately remove
distal lesions. This technique allows us to explore the segmental
branches that can appear patent at CT scan or angiography.
Dr Madani. I somewhat disagree with that approach, and I
don’t think it’s necessarily superior or equivalent to multiple
studies showing that you can have 1 circulatory arrest time. The
average time is approximately 15 to 20 minutes. You need approx-
imately 5 to 10 minutes just to have the bloodless field when you
get into distal vessels, and there are several studies that have shown
that approach to be safe. My second question relates to that
because in your series, the mortality is still approximately 6.9%.
Is that related to this or are you doing anything to improve on
the mortality overall.
Dr Grazioli.We think the mortality of 7% is the same when we
used the first technique. However, this mortality is high, 7% is
high, and this is due to the late referral of the patients at our center.diovascular Surgery c Volume 148, Number 3 1011
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tional class IV. For this reason, we try to discern this disease at
another center.
Dr Madani. My last question is related to the incidence of
tricuspid regurgitation. Approximately 20% of patients had mod-
erate or severe tricuspid regurgitation. Do you do anything with
those patients medically or surgically? Twenty percent with mod-
erate to severe disease seemed somewhat high.
Dr Grazioli. Generally we don’t treat tricuspid regurgitation
with surgery because after PEA there is right ventricle remodeling;
consequently, there is an improvement of tricuspid regurgitation.1012 The Journal of Thoracic and Cardiovascular SurWe have performed a study on right ventricle remodeling, and in
this study 70% of patients had moderate or severe regurgitation
before surgery, and after there was a reduction at 16%. Well, we
don’t say exactly the percentage of patients with moderate-severe
tricuspid regurgitation is high after surgery, but the reduction is
significant; however, we will try to improve this.
Dr Jose Pomar (Barcelona, Spain). So it means that you don’t
do tricuspid annuloplasty before?
Dr Grazioli. No.
Dr Pomar. You don’t do it?
Dr Grazioli. No, we don’t.gery c September 2014
